Vietnam's tender-tough approach to flattening drug prices
This article was originally published in Scrip
The idea of tendering is to secure the lowest possible price for a particular product through a competitive and ideally transparent bidding process. But when the system produces wildly variable results for an identical product in different areas, you know you've got a problem.
You may also be interested in...
Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.